Resource Summary Report

Generated by RRID on Jul 29, 2026

APC anti-human CD3

RRID:AB_314048
Type: Antibody

Proper Citation

BioLegend Cat# 300312, RRID:AB_314048

Antibody Information

URL: http://antibodyregistry.org/AB_314048

Proper Citation: BioLegend Cat# 300312, RRID:AB_314048

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_314048

Vendor: BioLegend

Catalog Number: 300312

Alternative Catalog Numbers: 300311

Record Creation Time: 20250820T053235+0000

Record Last Update: 20250820T214905+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD3.

No alerts have been found for APC anti-human CD3.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Yu S, et al. (2026) A CLOCK-targeting lncRNA induces trained immunity against tuberculosis. Cell host & microbe, 34(1), 68.

Wang X, et al. (2025) An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell, 188(16), 4225.

Wang D, et al. (2025) Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med (New York, N.Y.), 100749.

Stahl D, et al. (2025) CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer cell, 43(8), 1476.

Zhang T, et al. (2025) Humanized mouse model reveals T cell ANXA2 as a potential therapeutic target in ischemic stroke. iScience, 28(5), 112302.

Gu C, et al. (2025) An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. Cell reports. Medicine, 102515.

Cui L, et al. (2024) Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. Cancer research.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. Cell reports, 43(12), 115015.

Guimarães SJA, et al. (2024) Human papillomavirus infection affects the immune microenvironment and antigen presentation in penile cancer. Frontiers in oncology, 14, 1463445.

Nunoya JI, et al. (2024) Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties. International journal of molecular sciences, 25(16).

Wang X, et al. (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell, 187(18), 4890.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell, 187(18), 4905.

Ren X, et al. (2022) Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model. STAR protocols, 3(4), 101818.

Ye L, et al. (2022) A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell metabolism, 34(4), 595.

Yu B, et al. (2022) Engineered cell entry links receptor biology with single-cell genomics. Cell, 185(26), 4904.

Morton JJ, et al. (2021) Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. Molecular cancer research : MCR, 19(2), 346.

Hara T, et al. (2021) Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer cell, 39(6), 779.

Dong MB, et al. (2019) Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell, 178(5), 1189.